Firms

Ysios Capital

Ysios Capital

ysioscapital.com

Ysios Capital is a Spanish venture capital firm founded in 2008, with offices in Barcelona and San Sebastián. It invests globally in early- and mid-stage biotechnology companies developing novel therapeutic drugs and platforms for diseases with high unmet medical need. Its neuroscience portfolio includes Synendos, Engrail, Kynexis, Minoryx and Neurona. Alongside its established venture funds, its InceptionBio strategy focuses on company creation, technology transfer and early scientific projects, particularly in Spain.

Founded
—
Type
Venture capital

Funds2

  • InceptionBio—

    Biotech company-creation and early-stage fund focused on Spain, launched March 27, 2026 after completing a first closing. EUR100 million is its fundraising target; first-close commitments and exact private closing date are undisclosed. The strategy develops university and research-center science into new therapeutic companies.

  • Ysios BioFund III€216M

    Biotechnology fund investing in seed, early-stage and development-stage companies developing novel therapeutics for indications with high unmet medical need. Ysios announced the final closing at EUR216 million on 26 May 2021. It targets up to 15 companies across Europe and the US; the 2020 vintage is distinct from the 2021 closing announcement.

Team

Operations and support

Almudena MéndezAssociate
Antoni RibasVenture Partner
Arturo UrriosPartner
Carlos Garcia-EcheverriaVenture Partner
Carlos PayaVenture Partner
Catalina CuchyExecutive Assistant
Cristina GarmendiaGeneral Partner
David L. LaceyVenture Partner
Guillem LaportaPartner
Iñigo López-HuertaChief Financial Officer
Joan PerellóManaging Partner
Jordi XiolPartner
Joël Jean-MairetManaging Partner
Julia SalaverríaManaging Partner
Karen WagnerManaging Partner
Lance BermanVenture Partner
Laura ArgelichAssociate
Malgorzata RogalskaAssociate
María Vega de SeoaneController
Míriam CortésExecutive Assistant and Communications
Pamela KleinVenture Partner
Sriram BalusuAssociate
Thomas HarthPartner
Wen Wen ChengGeneral Counsel and Head of ESG

Co-investing

Investments